Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis

Cancer

Volumn 120, Issue 16, 2014, Pages 2432-2439

  Daskivich, Timothy J ^a   Lai, Julie ^b   Dick, Andrew W ^b   Setodji, Claude M ^b   Hanley, Janet M ^b   Litwin, Mark S ^a,b,c   Saigal, Christopher ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RAND CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; comorbidity; outcomes; prostate; survival

Indexed keywords

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DATA BASE; DEMOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; SOCIAL ASPECT; VERY ELDERLY; WATCHFUL WAITING; CANCER REGISTRY; EPIDEMIOLOGY; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; COMORBIDITY; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84905586023     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28757     Document Type: Article

References (22)

1. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011; 364: 1708-1717.
2. Daskivich TJ, Chamie K, Kwan L, et al. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer. 2011; 117: 4642-4650.
3. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL,. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011; 29: 1335-1341.
4. Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol. 2004; 171: 1513-1519.
5. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M,. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011; 18: 833-839.
6. Daskivich TJ, Kang-Hsien F, Koyama T, et al. Impact of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer. Ann Intern Med. 2013; 158: 709-717.
7. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131.
8. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8: 162-200.
9. Heidenreich A, Bellmunt J, Bolla M, et al. European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol. 2011; 59: 61-71.
10. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117: 2058-2066.
11. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS,. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009; 101: 888-892.
12. Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999; 91: 1719-1724.
13. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
14. Siegel R, Naishadam D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
15. National Institute of Diabetes and Digestive and Kidney Diseases. Table 14-15. Economic impact of urologic disease. In:, Litwin MS, Saigal CS, eds. Urologic Diseases in America. NIH Publication No. 12-7865. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office; 2012: 464-496.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
17. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
18. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
19. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
20. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974.
21. Klabunde CN, Harlan LC, Warren JL,. Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. Med Care. 2006; 44: 921-928.
22. Hadley J, Yabroff R, Barrett MJ, Penson DF, Saigal CS, Potosky A,. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst. 2010; 102: 1780-1793.